Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

HB 4014Session 89R

What changed between versions

11 paragraphs changed+40 words added−30 removed

Highlighted text was added in the newer version. Struck-through text was removed.

89R25425 MCF-D

By: Bucy, Oliverson, Pierson, Romero, et al.

H.B. No. 4014

Substitute the following for H.B. No. 4014:

By: VanDeaver

C.S.H.B. No. 4014

A BILL TO BE ENTITLED

9 unchanged paragraphs

AN ACT

relating to a study on the use of psychedelic therapies in the

treatment of certain conditions.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. (a) In this Act:

(1) "Commission" means the Health and Human Services

Commission.

(2) "Psychedelic therapies" means the use of

3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine

to treat mental health or other medical conditions.

(b) The commission, shallin conductconsultation awith studyBaylor on the useCollege of

Medicine and the Center for Psychedelic Research and Therapy at

Dell Medical School at The University of Texas at Austin, shall

conduct a study on the use of psychedelic therapies for treatment of post-traumatic stress

post-traumatic stress disorder, depression, and other co-occurring conditions.

conditions.

(c) In conducting the study, the commission shall:

45 unchanged paragraphs

(1) review clinical trials on the efficacy of using

psychedelic therapies in the treatment of post-traumatic stress

disorder, depression, and other co-occurring conditions;

(2) review current literature regarding the use of

psychedelic therapies in the treatment of post-traumatic stress

disorder, depression, and other co-occurring conditions;

(3) review actions of the United States Food and Drug

Administration regarding psychedelic therapies for treatment of

post-traumatic stress disorder, depression, and other co-occurring

conditions;

(4) evaluate treatment guidelines for use of

psychedelic therapies to treat post-traumatic stress disorder,

depression, and other co-occurring conditions and recommend

guidelines and best practices for providers; and

(5) evaluate patient access to current treatment for

post-traumatic stress disorder, depression, and other co-occurring

conditions and recommend legislative or other actions necessary to

ensure patient access to psychedelic therapies following approval

by the United States Food and Drug Administration, including

considerations of provider availability, affordability,

accessibility, training and licensure, and other regulatory

requirements.

(d) In addition to any money appropriated by the

legislature, the commission may solicit and accept federal funds

and gifts, grants, or donations from any source to administer and

finance the study conducted under this section.

(e) Not later than December 1, 2026, the commission shall

submit to the governor, the lieutenant governor, the speaker of the

house of representatives, and the chair of the standing committee

of each house of the legislature with primary jurisdiction over the

commission a written report that includes:

(1) the results of the study conducted under this

section; and

(2) any recommendations for legislative or other

action necessary to ensure patient access to psychedelic therapies

for treatment of post-traumatic stress disorder, depression, and

other co-occurring conditions after those therapies are approved by

the United States Food and Drug Administration.

(f) This Act expires September 1, 2027.

SECTION 2. The Health and Human Services Commission is

required to implement a provision of this Act only if the

legislature appropriates money specifically for that purpose. If

the legislature does not appropriate money specifically for that

purpose, the commission may, but is not required to, implement a

provision of this Act using other money available for that purpose.

SECTION 3. This Act takes effect September 1, 2025.

Back to the full text